Similar Effects of the Selective Noradrenaline Reuptake Inhibitor Atomoxetine on Three Distinct Forms of Impulsivity in the Rat
The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Atomoxetine is a noradrenaline-specific reuptake inhibitor used clinically for the treatment of childhood and adult attention deficit hyperactivity disorder (ADHD). Studies in human volunteers and patient groups have shown that atomoxetine improves stop-signal reaction time (SSRT) performance, an effect consistent with a reduction in motor impulsivity. However, ADHD is a heterogeneous disorder and it is of interest to determine whether atomoxetine is similarly effective against other forms of impulsivity, as well as the attentional impairment present in certain subtypes of ADHD. The present study examined the effects of atomoxetine on impulsivity using an analogous SSRT task in rats and two additional tests of impulsivity; delay discounting of reward and the five-choice serial reaction time task (5CSRTT), the latter providing an added assessment of sustained visual attention. Atomoxetine produced a significant dose-dependent speeding of SSRT. In addition, atomoxetine produced a selective, dose-dependent decrease in premature responding on the 5CSRTT. Finally, on the delay-discounting task, atomoxetine significantly decreased impulsivity by increasing preference for the large-value reward across increasing delay. These findings conclusively demonstrate that atomoxetine decreases several distinct forms of impulsivity in rats. The apparent contrast of these effects with stimulant drugs such as amphetamine and methylphenidate, which generally act to increase impulsivity on the 5CSRTT, may provide new insights into the mechanisms of action of stimulant and nonstimulant drugs in ADHD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Atomoxetine improves measures of PFC cognitive function in rats (Newman et al., 2008; Robinson et al., 2008; Seu et al., 2009), monkeys (Gamo et al., 2010; Seu et al., 2009), and humans (Chamberlain et al., 2007; Chamberlain et al., 2006).”
From Catecholamine influences on prefrontal cortical function: Relevance to treatment of attention deficit/hyperactivity disorder and related disorders (2011) · cites this paper as Robinson et al., 2008
In the citing paper
“For example, atomoxetine, a relatively selective norepinephrine uptake inhibitor, improves response inhibition in both the 5-CRSTT and the stop-signal task (Robinson et al 2008).”
From Prefrontal cortex executive processes affected by stress in health and disease (2018) · cites this paper as Robinson et al 2008
Citations
Cites
On the ability to inhibit thought and action: a theory of an act of control
Logan, G. D., & Cowan, W. B. (1984) · Psychological Review · doi:10.1037/0033-295x.91.3.295 · Cited by 2,590 · cited 1×
“Recently, atomoxetine has been shown to improve performance in normal human volunteers in a stop-signal reaction time (SSRT) task (Chamberlain et al, 2006), which provides a measure of motor inhibition and the propensity toward behavioral impulsivity (Logan and Cowan, 1984).”
BackgroundInhibitory Processes in Attention, Memory and Language
Carr, T. H., & Dagenbach, D. (1994) · Medical Entomology and Zoology · Cited by 2,364
Stop-signal inhibition disrupted by damage to right inferior frontal gyrus in humans
Aron, A. R., Fletcher, P. C., Bullmore, E. T., Sahakian, B. J., & Robbins, T. W. (2003) · Nature Neuroscience · doi:10.1038/nn1003 · Cited by 1,771 · cited 2×
“…rights reserved 0893-133X/08 $30.00 www.neuropsychopharmacology.org improved, in both humans and rodents, by stimulants such as methylphenidate (Tannock et al, 1989; Aron et al, 2003b; Eagle et al, 2007b) and by the anti-narcoleptic agent modafinil (Turner et al, 2003, 2004; Eagle et al, 2007b).”
BackgroundInfluentialSelf-citationPrefrontal executive and cognitive functions in rodents: neural and neurochemical substrates
Dalley, J. W., Cardinal, R. N., & Robbins, T. W. (2004) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2004.09.006 · Cited by 1,329 · cited 2×
“Subjects were trained to detect the location of a brief visual stimulus (0.5 s in duration) presented pseudorandomly in one of five apertures over a large number of trials, as described previously (Dalley et al, 2004).”
MethodInfluentialSelf-citationThe 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry
Robbins, T. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1154-7 · Cited by 1,282 · cited 3×
“The 5CSRTT also allows for the measurement of attentional capacity because of its requirement for rats to detect brief visual targets (Robbins, 2002).”
BackgroundMethodSelf-citationBymaster, F. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00346-9 · Cited by 1,123 · cited 7×
“Neuropsychopharmacology striatal DA (Bymaster et al, 2002).”
BackgroundInfluentialOn the ability to inhibit thought and action: A users' guide to the stop signal paradigm
Logan, G. D. (1994) · UvA-DARE (University of Amsterdam) · Cited by 1,115
Neurobiology of Executive Functions: Catecholamine Influences on Prefrontal Cortical Functions
Arnsten, A. F. T., & Li, B.-M. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.08.019 · Cited by 948 · cited 1×
“…with stimulant and nonstimulant medications have shown that atomoxetine, amphetamine, and methylphenidate all enhance DA and NA in the PFC (for review see Solanto, 1998; Arnsten and Li, 2005; Arnsten, 2006a, b) but atomoxetine does not increase DA in the nucleus accumbens (Bymaster et al, 2002).”
BackgroundImpulsive choice induced in rats by lesions of the nucleus accumbens core
Cardinal, R. N., Pennicott, D. R., Lakmali, C., Sugathapala, Robbins, T. W., & Everitt, B. J. (2001) · Science · doi:10.1126/science.1060818 · Cited by 923 · cited 1×
“For example, lesions of the nucleus accumbens core region impair delay discounting by enhancing impulsive choice (Cardinal et al, 2001) but have no effect on SSRT (Eagle and Robbins, 2003b).”
BackgroundSelf-citationRubia, K., Smith, A. B., Brammer, M. J., & Taylor, E. (2003) · NeuroImage · doi:10.1016/s1053-8119(03)00275-1 · Cited by 852 · cited 1×
“SSRT itself is especially susceptible to damage to the right inferior frontal cortex in humans (Aron et al, 2003a; Rubia et al, 2003), and in rats following damage to the ventral orbitofrontal cortex, but not the prelimbic or infralimbic prefrontal cortex (PFC) (Eagle and Robbins, 2003b; Eagle et…”
Background
Cited by
Items 201–300 of 369
Caballero-Puntiverio, M., Lerdrup, L., Arvastson, L., Aznar, S., & Andreasen, J. T. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.109823 · Cited by 23
Jones, J. A., Zühlsdorff, K., & Dalley, J. W. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15380 · Cited by 23
“…responses Robinson et al. (2008) 5- CSRTT Prazosin ɑ1- adrenoceptor antagonist S.C ↑ premature responses Koskinen et al. (2003) DDT Atomoxetine Selective NA reuptake inhibitor I.P ↓ delay aversion Robinson et al. (2008) DDT Phenylephrine ɑ1- adrenoceptor agonist I.P ↑ delay aversion van…”
Self-citationSilveira, M. M., Murch, W. S., Clark, L., & Winstanley, C. A. (2015) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000203 · Cited by 23
“…the impulse control deficits in ADHD, and in both humans and rodents, it has been shown to decrease impulsivity in tests of impulsive choice and impulsive action (Chamberlain et al., 2007; Navarra et al., 2008; Robinson et al., 2008; Bari et al., 2009; Barry et al., 2009; Sun et al., 2012).”
BackgroundInfluentialModelling human drug abuse and addiction with dedicated small animal positron emission tomography
Dalley, J. W., Fryer, T. D., Aigbirhio, F. I., Brichard, L., Richards, H. K., Hong, Y. T., Baron, J., Everitt, B. J., & Robbins, T. W. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.05.029 · Cited by 23
Self-citationBroos, N., Loonstra, R., van Mourik, Y., Schetters, D., Schoffelmeer, A. N. M., Pattij, T., & Vries, T. J. D. (2014) · Addiction Biology · doi:10.1111/adb.12168 · Cited by 21
“…acute challenges with a similar dose of atomoxetine were found to decrease the preference for the large reward in the DRT (Broos et al. 2012a), a finding that appeared at odds with an earlier study demonstrating beneficial effects of atomoxetine on impulsive decision making (Robinson et al. 2008).”
BackgroundResultPhillips, A. G., Geyer, M. A., & Robbins, T. W. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.01.014 · Cited by 22
Self-citationCabbia, R., Consoli, A., & Suchecki, D. (2018) · Stress · doi:10.1080/10253890.2018.1456525 · Cited by 25
“, 2010) or inhibit impulsive behavior (Robinson et al., 2008).”
BackgroundDommett, E. J. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2014.06.001 · Cited by 22
“As outlined in the introduction, themajority of studies in healthy animals have shown a decrease in premature responding following ATX treatment (Baarendse and Vanderschuren, 2012; Blondeau and Dellu-Hagedorn, 2007; Fernando et al., 2012; Paterson et al., 2012; Robinson et al., 2008), which we did not find in the curr…”
InfluentialMarek, G. J. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.191718 · Cited by 21
Sim, J., Kim, E., Yang, W., Woo, S., & In, S. (2017) · Forensic Science International · doi:10.1016/j.forsciint.2017.01.001 · Cited by 20
Fontana, B. D., Reichmann, F., Tilley, C. A., Lavlou, P., Shkumatava, A., Alnassar, N., Hillman, C., Karlsson, K. Æ., Norton, W., & Parker, M. O. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02601-4 · Cited by 22
“1 − / − performed a higher number of incorrect responses than WT in the 5-CSRTT test day. the increased cognitive demands of the test phase [31], these data suggest attentional de fi cits in adgrl3.”
BackgroundInfluentialNishitomi, K., Yano, K., Kobayashi, M., Jino, K., Kano, T., Horiguchi, N., Shinohara, S., & Hasegawa, M. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.02.022 · Cited by 22
Wagner, G., Krause-Utz, A., de la Cruz, F., Schumann, A., Schmahl, C. G., & Bär, K. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.01.009 · Cited by 21
“For instance, the selective NA reuptake inhibitor atomoxetine (ATX) has a significant anti-impulsivity effect in rodents in several impulsivity tests such as the stop-signal reaction task (SSRT), which is a paradigm used to measure motor impulsivity (Robinson et al., 2008).”
BackgroundLister hooded rats as a novel animal model of attention-deficit/hyperactivity disorder
Jogamoto, T., Utsunomiya, R., Sato, A., Kihara, N., Choudhury, M. E., Miyanishi, K., Kubo, M., Nagai, M., Nomoto, M., Yano, H., et al. (2020) · Neurochemistry International · doi:10.1016/j.neuint.2020.104857 · Cited by 20
Juárez, J., & Guerrero-Álvarez, Á. (2015) · Behavioral Neuroscience · doi:10.1037/bne0000109 · Cited by 20
Benn, A., & Robinson, E. S. J. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4458-8 · Cited by 21
“Drug doses used were based on previous studies by using similar behavioral tasks (Murphy et al. 2008; Robinson 2012; Robinson et al. 2008).”
BackgroundMethodInfluentialSelf-citationImpulsivity, Risky Choice, and Impulse Control Disorders
Robbins, T. W., & Dalley, J. W. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-805308-9.00007-5 · Cited by 22
Self-citationCallahan, P. M., & Terry, A. V. (2015) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-16522-6_5 · Cited by 24
Radin, D. P., Zhong, S., Cerne, R., Shoaib, M., Witkin, J. M., & LIPPA, A. S. (2024) · Future Pharmacology · doi:10.3390/futurepharmacol4010012 · Cited by 18
“Responses during inter-trial intervals were recorded as premature responses and were expressed as percentage premature responses calculated as described by Robinson et al. [40].”
MethodHavranek, M. M., Hulka, L. M., Tasiudi, E., Eisenegger, C., Vonmoos, M., Preller, K. H., Mößner, R., Baumgartner, M. R., Seifritz, E., Grünblatt, E., et al. (2015) · Addiction Biology · doi:10.1111/adb.12324 · Cited by 22
“Studies performed in rats and in humans revealed that the NE reuptake inhibitor atomoxetine improved performance and decreased premature responding in stop-signal reaction time tasks (as an example for motor impulsivity) (Robinson et al. 2008; Bari & Robbins 2013).”
BackgroundGenetic influences on delayed reward discounting: A genome-wide prioritized subset approach.
MacKillop, J., Gray, J. C., Weafer, J. J., Sanchez‐Roige, S., Palmer, A. A., & de Wit, H. (2019) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000227 · Cited by 17
Fitzpatrick, C. M., & Andreasen, J. T. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.01.038 · Cited by 18
Yates, J. R. (2019) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000239 · Cited by 16
“…al., 2017; Liu, Wilkinson, & Robbins, 2017; Mendez et al., 2012; Paine, Drigenberg, & Olmstead, 2003; Paterson, Wetzler, Hackett, & Hanania, 2012; Robinson et al., 2008; Schippers, Schetters, De Vries, & Pattij, 2016; Schneider et al., 2011; Sukhotina et al., 2008; Sun, Cocker, Zeeb, &…”
The Neuropharmacology of Impulsive Behaviour, an Update
Pattij, T., & Vanderschuren, L. J. M. J. (2020) · Current topics in behavioral neurosciences · doi:10.1007/7854_2020_143 · Cited by 17
Sex differences in nicotine-induced impulsivity and its reversal with bupropion in rats
Íbias, J., & Nazarian, A. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120937543 · Cited by 16
“Increase in dopamine and norepinephrine levels have been implicated in decreasing impulsivity (Navarra et al., 2008; Pattij et al., 2007; Robinson et al., 2008; Tsutsui-Kimura et al., 2009).”
BackgroundThe Neurobiology of Impulsive Decision-Making and Reinforcement Learning in Nonhuman Animals
Groman, S. M. (2020) · Current topics in behavioral neurosciences · doi:10.1007/7854_2020_127 · Cited by 17
The association between in vivo central noradrenaline transporter availability and trait impulsivity
Hesse, S., Müller, U., Rullmann, M., Luthardt, J., Bresch, A., Becker, G., Zientek, F., Patt, M., Meyer, P., Blüher, M., et al. (2017) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2017.06.013 · Cited by 16
“Previous investigations into the role of NA in impulsivity employed systemic administration of specific receptor agonists and antagonists as well as NAT inhibitors (Robinson et al., 2008).”
Giller, F., Mückschel, M., Ziemssen, T., & Beste, C. (2020) · Cortex · doi:10.1016/j.cortex.2020.03.008 · Cited by 16
Ptukha, M. A., Fesenko, Z. S., Belskaya, A. D., Gromova, A. A., Pelevin, A., Kurzina, N. P., Gainetdinov, R. R., & Volnova, A. B. (2022) · Biomolecules · doi:10.3390/biom12101484 · Cited by 16
Ye, R., Hezemans, F. H., O’Callaghan, C., Tsvetanov, K. A., Rua, C., Jones, P. S., Holland, N., Malpetti, M., Murley, A. G., Barker, R. A., et al. (2023) · Journal of Neuroscience · doi:10.1523/jneurosci.0289-22.2023 · Cited by 18
Self-citationTsutsui‐Kimura, I., Ohmura, Y., Izumi, T., Kumamoto, H., Yamaguchi, T., Yoshida, T., & Yoshioka, M. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2835-5 · Cited by 17
Milnacipran Remediates Impulsive Deficits in Rats with Lesions of the Ventromedial Prefrontal Cortex
Tsutsui‐Kimura, I., Yoshida, T., Ohmura, Y., Izumi, T., & Yoshioka, M. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu083 · Cited by 17
“, 2007) and the acute administration of NRIs, such as atomoxetine, suppress impulsive action (Blondeau and Dellu-Hagedron, 2007; Robinson et al., 2008; Paterson et al., 2011; Fernando et al., 2012), SSRIs, NRIs, and SNRIs, including milnacipran, might be Figure 7.”
BackgroundAtomoxetine and citalopram alter brain network organization in Parkinson’s disease
Borchert, R. J., Rittman, T., Rae, C. L., Passamonti, L., Jones, S. P., Vatansever, D., Vázquez Rodríguez, P., Ye, Z., Nombela, C., Hughes, L. E., et al. (2019) · Brain Communications · doi:10.1093/braincomms/fcz013 · Cited by 14
Self-citationZhukovsky, P., Morein‐Zamir, S., Ziauddeen, H., Fernández-Egea, E., Meng, C., Regenthal, R., Sahakian, B. J., Bullmore, E. T., Robbins, T. W., Dalley, J. W., et al. (2021) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2021.08.010 · Cited by 19
Self-citationOptogenetic and pharmacological interventions link hypocretin neurons to impulsivity in mice
Tyree, S. M., Jennings, K. J., Gonzalez, O. C., Li, S., Nicholson, J. R., von Heimendahl, M., & de Lecea, L. (2023) · Communications Biology · doi:10.1038/s42003-023-04409-w · Cited by 14
Chernoff, C. S., Hynes, T. J., Schumacher, J. D., Ramaiah, S., Avramidis, D. K., Mortazavi, L., Floresco, S., & Winstanley, C. A. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06508-2 · Cited by 16
“Noradrenaline itself is known to be a potent regulator of impulsive action (Bari et al. 2009; Chamberlain & Sahakian 2007; Robinson et al. 2008), with the anti-impulsivity properties of noradrenergic drugs like atomoxetine well-established in the literature (Bari et al. 2009; Economidou et al.…”
Opposite Effects of Amphetamine on Impulsive Action with Fixed and Variable Delays to Respond
Hayton, S. J., Maracle, A. C., & Olmstead, M. C. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.236 · Cited by 14
Sasamori, H., Ohmura, Y., Yoshida, T., & Yoshioka, M. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.11.041 · Cited by 17
Investigating a race model account of executive control in rats with the countermanding paradigm
Beuk, J., Beninger, R. J., & Paré, M. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.01.014 · Cited by 14
“…namely generating unstable go trial accuracy or non-increasing probabilities of response inhibition as SSD lengthened (Eagle and Robbins, 2003a,b, 2008; Pattij et al., 2007, 2009; Robinson et al., 2008; Bari et al., 2009, 2011; Eagle et al., 2011); however, these data were not explicitly displayed.”
BackgroundMethodFurlong, T. M., Leavitt, L. S., Keefe, K. A., & Son, J. (2016) · Neurotoxicity Research · doi:10.1007/s12640-016-9605-9 · Cited by 13
“…drugs that specifically improve stop-trial accuracy (e.g., modafinil or atomoxetine) may be more beneficial to METH abusers (Eagle et al. 2007; Robinson et al. 2008), and drugs that improve go processes (e.g., methylphenidate, propranolol or prazosin) may be more beneficial to AMPH abusers…”
Yates, J. R. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4825-0 · Cited by 13
“…1 vs. 4 [Baarendse and Vanderschuren 2012; Cardinal et al. 2000; Eubig et al. 2014; Higgins et al. 2016; Korte et al. 2017; Liu et al. 2004, 2017; Robinson et al. 2008; Schippers et al. 2016; Stanis et al. 2008; Sukhotina et al. 2008; Sun et al. 2012; Talpos et al. 2006; van den Bergh et al.…”
InfluentialOzga‐Hess, J. E., & Anderson, K. G. (2019) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000500 · Cited by 13
“, 2016) and reduced delay discounting significantly (Dela Peña et al., 2017; Juarez et al., 2015; Nishitomi et al., 2018; Robinson et al., 2008).”
BackgroundContrasting effects of d-amphetamine and atomoxetine on measures of impulsive action and choice
Higgins, G. A., Brown, M., MacMillan, C., Silenieks, L. B., & Thevarkunnel, S. (2021) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2021.173220 · Cited by 12
Mapping neuromodulatory systems in Parkinson’s disease: lessons learned beyond dopamine
Ye, Z. (2022) · Current Medicine · doi:10.1007/s44194-022-00015-w · Cited by 13
A mechanistic overview of approaches for the treatment of psychostimulant dependence
Jensen, K. L., Jensen, S. B., & Madsen, K. L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.854176 · Cited by 14
DIY-NAMIC Behavior: A High-Throughput Method to Measure Complex Phenotypes in the Homecage
Lee, J. H., Capan, S., Lacefield, C., Shea, Y. M., & Nautiyal, K. M. (2020) · eNeuro · doi:10.1523/eneuro.0160-20.2020 · Cited by 14
Sex differences in noradrenergic modulation of attention and impulsivity in rats
Mei, X., Wang, L., Yang, B., & Li, X. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05841-8 · Cited by 13
Aberrant Dopamine Transmission and Cognitive Dysfunction in Animal Models of Parkinson's Disease
Lelos, M. J., & Dunnett, S. B. (2011) · Journal of Parkinson s Disease · doi:10.3233/jpd-2011-11036 · Cited by 12
“Interestingly, atomoxetine, a noradrenaline-specific reuptake inhibitor, has been shown in human and animal studies to increase the stop-signal reaction time on this task [100, 102].”
BackgroundThe impact of l-dopa on attentional impairments in a rat model of Parkinson’s disease
Smith, E. S., Hardy, G. A., Schallert, T. J., & Lee, H. J. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.09.022 · Cited by 11
Humby, T., Smith, G. E., Small, R., Davies, W., Carter, J., Bentley, C. A., Winstanley, C. A., Rogers, R. D., & Wilkinson, L. S. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05496-x · Cited by 11
An Overview of Measuring Impulsive Behavior in Mice
Dent, C. L., & Isles, A. R. (2014) · Current Protocols in Mouse Biology · doi:10.1002/9780470942390.mo140015 · Cited by 11
Lei, X., Chen, C., He, Q., Moyzis, R. K., Xue, G., Chen, C., Cao, Z., Li, J., Li, H., Zhu, B., et al. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.266 · Cited by 13
Phenomenology and Epidemiology of Pathological Skin Picking
Odlaug, B. L., & Grant, J. E. (2012) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780195389715.013.0070 · Cited by 11
Xu, B., He, T., Lü, Y., Jia, J., Sahakian, B. J., Robbins, T. W., Jin, L., & Ye, Z. (2022) · NeuroImage Clinical · doi:10.1016/j.nicl.2022.103276 · Cited by 10
“In rats, atomoxetine can produce a dose-dependent speeding of SSRT (Bari et al., 2009; Bari et al., 2011; Robinson et al., 2008).”
BackgroundSelf-citationNewman, L. A., Baraiolo, J., Mokler, D. J., Rabinowitz, A. G., Galler, J. R., & McGaughy, J. A. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00123 · Cited by 10
Effect of atomoxetine on ADHD-pain hypersensitization comorbidity in 6-OHDA lesioned mice
Sifeddine, W., Ba-M’hamed, S., Landry, M., & Bennis, M. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00459-3 · Cited by 12
Methylphenidate has nonlinear dose effects on cued response inhibition in adults but not adolescents
Simon, N. W., & Moghaddam, B. (2016) · Brain Research · doi:10.1016/j.brainres.2016.07.027 · Cited by 10
Browne, C. J., Soko, A. D., & Fletcher, P. J. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3602-6 · Cited by 10
“Evidence also suggests that NE may have an inhibitory role on impulsivity and incentive motivation since the selective NET inhibitor atomoxetine decreases premature responding in the 5-choice task (Robinson et al. 2008) and responding for conditioned reinforcing stimuli on a secondorder schedule of reinforcement (Econ…”
BackgroundKnauth, K., & Peters, J. (2022) · Psychophysiology · doi:10.1111/psyp.13996 · Cited by 11
Phase synchrony between prefrontal noradrenergic and cholinergic signals indexes inhibitory control
Liu, Y., Nong, Y., Feng, J., Li, G., Sajda, P., Li, Y., & Wang, Q. (2025) · Nature Communications · doi:10.1038/s41467-025-62317-5 · Cited by 14
Gell, M., Langner, R., Küppers, V., Cieslik, E. C., Satterthwaite, T. D., Eickhoff, S. B., & Müller, V. I. (2024) · Imaging Neuroscience · doi:10.1162/imag_a_00295 · Cited by 8
“Outside psychostimulants, dopamine is classically associated with addiction (Berke & Hyman, 2000; Wise & Robble, 2020) and has been suggested as a major candidate for passing reward prediction errors within the valuation system (Nasser, Calu, Schoenbaum, & Sharpe, 2017).”
BackgroundAlén, F., Serrano, A., Gorriti, M. Á., Pavón, F. J., Orío, L., de Heras, R. G., Ramírez-López, M. T., Antón, M., Pozo, M. A., & de Fonseca, F. R. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114571400087x · Cited by 8
Beta-adrenoreceptor blockade abolishes atomoxetine-induced risk taking
Yang, F. N., Pan, J. S., & Li, X. (2015) · Physiology & Behavior · doi:10.1016/j.physbeh.2015.10.032 · Cited by 10
Benn, A., & Robinson, E. S. J. (2024) · Cognitive Affective & Behavioral Neuroscience · doi:10.3758/s13415-023-01152-x · Cited by 8
“All drugs were prepared fresh each day and dosed in a final volume of 1 ml/kg. Doses used were based on previous behavioral studies (Benn & Robinson, 2017; Murphy et al., 2008; Robinson, 2012; Robinson et al., 2008) and administered by using a refined injection method (Stuart & Robinson, 2015).”
MethodSelf-citationBizot, J., Cogrel, N., Massé, F., Chauvin, V., Brault, L., David, S., & Trovero, F. (2015) · Psychopharmacology · doi:10.1007/s00213-015-3974-2 · Cited by 9
“Other studies showed that atomoxetine and methylphenidate did not improve attention or improved attention only in poor performing rats (Fernando et al. 2012; Robinson et al. 2008; Robinson 2012).”
ResultImproving the Translational Validity of Methods Used to Study Depression in Animals
Robinson, E. S. J. (2016) · Psychopathology Review · doi:10.5127/pr.034713 · Cited by 11
“Studies in the 5-choice serial reaction time task (Robbins, 2002) have found that noradrenaline plays an important role in effortful attention and impulse control (Robinson et al., 2008; Milstein, Lehmann, Theobald, Dalley, & Robbins, 2007).”
BackgroundSelf-citationSkvortsova, V., & Hauser, T. U. (2022) · Research Square · doi:10.21203/rs.3.rs-1280535/v1 · Cited by 9
Noradrenergic modulation of saccades in Parkinson’s disease
Orlando, I. F., Hezemans, F. H., Ye, R., Murley, A. G., Holland, N., Regenthal, R., Barker, R. A., Williams‐Gray, C. H., Passamonti, L., Robbins, T. W., et al. (2024) · Brain Communications · doi:10.1093/braincomms/fcae297 · Cited by 7
“72,73 In a related domain, noradrenaline is implicated in the ability to shift responding from an established attentional set to a new set of responses.”
Self-citationMagnard, R., Fouyssac, M., Vachez, Y. M., Cheng, Y., Dufourd, T., Carcenac, C., Boulet, S., Janak, P. H., Savasta, M., Belin, D., et al. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02804-3 · Cited by 7
Obsessive–compulsive spectrum and disorders of the skin
Grant, J. E., & Odlaug, B. L. (2009) · Expert Review of Dermatology · doi:10.1586/edm.09.40 · Cited by 10
Beckenstrom, A., Coloma, P., Dawson, G., Finlayson, A., Malik, A., Post, A., Steiner, M., & Potenza, M. (2023) · Neuroscience and Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105107 · Cited by 7
Radin, D. P., Zhong, S., Cerne, R., Shoaib, M., Witkin, J. M., & LIPPA, A. S. (2024) · Future Medicinal Chemistry · doi:10.1080/17568919.2024.2401312 · Cited by 6
Azocar, V. H., Petersson, P., Fuentes, R., & Fuentealba, J. A. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111064 · Cited by 6
Maguire, D. R., & France, C. P. (2019) · Psychopharmacology · doi:10.1007/s00213-019-5183-x · Cited by 6
Netter, P. (2021) · Neuropsychobiology · doi:10.1159/000514074 · Cited by 6
Prichardt, S., Caballero-Puntiverio, M., Klem, L., Arvastson, L., Lerdrup, L., & Andreasen, J. T. (2022) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2022.109749 · Cited by 6
Atomoxetine modulates the relationship between perceptual abilities and response bias
Guedj, C., Reynaud, A. J., Monfardini, E., Salemme, R., Farnè, A., Meunier, M., & Hadj‐Bouziane, F. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05336-7 · Cited by 7
Executive functioning: perspectives on neurotrophic activity and pharmacology
Sun, M. (2018) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000427 · Cited by 5
Atomoxetine Reduces Decisional Impulsivity in Human Cocaine Addiction
Lim, T. V., Cardinal, R. N., Ziauddeen, H., Regenthal, R., Sahakian, B. J., Robbins, T. W., & Ersche, K. D. (2024) · Biological Psychiatry · doi:10.1016/j.biopsych.2024.10.018 · Cited by 6
Self-citationTranslational Pharmacology of a Putative Measure of Motor Impulsivity in Larval Zebrafish
Parker, M. O., & Brennan, C. H. (2016) · Current Psychopharmacologye · doi:10.2174/2211556005666160526111902 · Cited by 5
Park, D., Mabunga, D. F. N., Adil, K. J., Ryu, O., Valencia, S. T., Kim, R.-E., Kim, H. J., Cheong, J. H., Kwon, K. J., Kim, H. Y., et al. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108494 · Cited by 5
Genotype-by-diagnosis interaction influences self-control in human cocaine addiction
Graczyk, M. M., Sahakian, B. J., Robbins, T. W., & Ersche, K. D. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02347-z · Cited by 5
Self-citationKoloski, M. F., Terry, A., Lee, N., & Ramanathan, D. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1385502 · Cited by 6
Dürtüselliğin Nöroanatomik ve Nörokimyasal Temelleri
Yazıcı, K. U., & Yazıcı, A. (2010) · doi:10.18863/pgy.83834 · Cited by 32
Deficits in Reward System Activation and Impulsivity: A Predisposing Condition to Alcoholism?
Duka, T. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.02.002 · Cited by 5
The Neuroanatomy and Neurochemistry of Response Inhibition
Forstmann, B. U., & Alkemade, A. (2017) · Wiley eBooks · doi:10.1002/9781118920497.ch16 · Cited by 6
Redding, Z. V., Chawla, P. A., & Sabol, K. E. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05329-6 · Cited by 5
Ye, R., Mazibuko, N., Teichert, J., Regenthal, R., Kehagia, A. A., & Mehta, M. A. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05998-2 · Cited by 5
“2002), modulates SST performance in experimental animals (Bari et al. 2009; Robinson et al. 2008), healthy human subjects (Chamberlain et al.”
BackgroundThe Neurochemical Modulation of Prefrontal Control Processes
Robbins, T. W., & Kehagia, A. A. (2017) · The Wiley Handbook of Cognitive Control · doi:10.1002/9781118920497.ch19 · Cited by 4
Self-citationKyriakidou, M., Caballero-Puntiverio, M., Andreasen, J. T., & Thomsen, M. (2023) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2023.110841 · Cited by 4
“, 2014), but there are also reports of both a decrease (Nishitomi et al., 2018; Robinson et al., 2008) and an increase in delay discounting following atomoxetine treatment (Broos et al.”
BackgroundChernoff, C. S., Belin‐Rauscent, A., Puaud, M., Torrisi, S. A., Fouyssac, M., Németh, B., Yu, C., Higuera‐Matas, A., Jones, S., & Belin, D. (2025) · Biological Psychiatry · doi:10.1016/j.biopsych.2025.07.012 · Cited by 4
Considerations on nonclinical approaches to modeling risk factors of suicidal ideation and behavior
Goody, S. M. G., Cannon, K., Liu, M., Kallman, M. J., Martinolle, J.-P., Mazelin-Winum, L., Giarola, A., Ardayfio, P. A., Moyer, J. A., Teuns, G., et al. (2017) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2017.07.030 · Cited by 4
Vigilance demand and the effects of stimulant drugs in a five-choice reaction-time procedure in mice
Katz, J. L., Kohut, S. J., & Soto, P. L. (2018) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000435 · Cited by 4
“However, atomoxetine is useful in treating ADHD, and mixed effects have previously been reported on variants of the 5-CSRT procedures (Navarra et al., 2007; Robinson et al., 2008; Koffarnus and Katz, 2011).”
The Effects of Drug Treatments for ADHD in Measures of Cognitive Performance
Higgins, G. A., & Silenieks, L. B. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_341 · Cited by 4
Duka, T., & Crews, F. T. (2009) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2009.06.011 · Cited by 4
Tomassini, A., Hezemans, F. H., Ye, R., Cam‐CAN, Tsvetanov, K. A., Wolpe, N., & Rowe, J. B. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.29.450427 · Cited by 4
Trait Impulsivity as a Feature of Parkinson’s Disease Treatment and Progression
Spencer, H., & Anderton, R. S. (2024) · Parkinson s Disease · doi:10.1155/2024/8770997 · Cited by 4
Bari, A., Robbins, T. W., & Dalley, J. W. (2010) · Neuromethods · doi:10.1007/978-1-60761-934-5_14 · Cited by 4
Self-citationMakulska-Gertruda, E., Hauser, J., Sontag, T. A., & Lange, K. W. (2014) · Functional Foods in Health and Disease · doi:10.31989/ffhd.v4i7.4 · Cited by 3
“Previous studies investigating the effects of impulsivity on behavior used premature responses as sole parameter [62, 63].”
BackgroundThe Genetics of Impulsivity: A Synthesis of Findings in Humans and Rodent Models
Jupp, B., & Dalley, J. W. (2016) · Springer eBooks · doi:10.1007/978-1-4939-3777-6_3 · Cited by 3
Self-citation
Metadata
- Authors
- Robinson, E. S. J., Eagle, D. M., Mar, A. C., Bari, A., Banerjee, G., Jiang, X., Dalley, J. W., & Robbins, T. W.
- Affiliations
- University of Cambridge (GB)
- Corresponding author
- Eagle, Dawn M
- ORCID
- Venue
- Neuropsychopharmacology
- Published
- 2007-07-18
- Volume
- 33
- Issue
- 5
- Pages
- 1028-1037
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W1992488100
- Cited by
- 359
- References
- 66
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 16 · 2023: 11 · 2022: 15 · 2021: 17 · 2020: 13 · 2019: 10 · 2018: 18 · 2017: 21 · 2016: 21 · 2015: 20 · 2014: 37 · 2013: 23 · 2012: 25
- FWCI
- 12.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Bristol Research (University of Bristol) (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Explore Bristol Research (submittedVersion)
- Funders
- Wellcome Trust
- British Pharmacological Society
- Research Councils UK
- Medical Research Council
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cognitive Neuroscience › Neural and Behavioral Psychology Studies
- Keywords
- atomoxetine, impulsivity, attention deficit hyperactivity disorder, norepinephrine reuptake inhibition, stop-signal reaction time, delay discounting, 5-choice serial reaction time task, visual attention, stimulants, amphetamine, methylphenidate, rats
- MeSH terms
- Atomoxetine Hydrochloride, Analysis of Variance, Animals, Behavior, Animal, Choice Behavior, Dose-Response Relationship, Drug, Impulsive Behavior, Inhibition, Psychological, Male, Propylamines, Reaction Time, Reinforcement, Psychology, Reinforcement Schedule, Task Performance and Analysis, Adrenergic Uptake Inhibitors, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.